Figure 6
Expression of HOXA1 is associated with shortened overall survival of patients with OSCC. (A) The overall survival analysis according to the Kaplan-Meier method for HOXA1 immunoexpression revealed that high HOXA1 expression is associated with poor prognosis with a 5-year survival of 55.5% (p = 0.0073). (B) Disease-specific overall survival for patients with high expression of HOXA1 was even shorter (p = 0.0048). (C) Five-year disease-free survival was not associated with HOXA1 immunoexpression in OSCC tumors (p = 0.27).